Unknown

Dataset Information

0

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.


ABSTRACT: LESSONS LEARNED:The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate-resistant prostate cancer (mCRPC).The negative data underscore that, despite a sound biological rationale and supportive early-phase clinical results, adding antiangiogenic agents to docetaxel for mCRPC is a great challenge. BACKGROUND:Inhibition of vascular endothelial growth factor (VEGF) signaling abrogates tumor-induced angiogenesis to constrain tumor growth, and can be exploited therapeutically by using cediranib, an oral tyrosine kinase inhibitor of VEGF receptor signaling. Our preliminary phase I trial data showed that adding cediranib to docetaxel plus prednisone (DP) was safe and feasible, with early evidence for efficacy in patients with metastatic castrate-resistant prostate cancer (mCRPC). METHODS:This multicenter phase II trial assessed whether adding cediranib to DP improves efficacy of DP in patients with mCRPC. Chemotherapy-naive patients with mCRPC were randomly assigned to receive either docetaxel (75 mg/m2 intravenously every 3 weeks) with prednisone (5 mg twice daily) plus cediranib (30 mg once daily; the DP+C arm) or DP only (the DP arm). The primary endpoint was to compare 6-month progression-free survival (PFS) rate between the two arms. Secondary endpoints included 6-month overall survival (OS), objective tumor and prostate-specific antigen (PSA) response rates, biomarkers, and adverse events. RESULTS:The 6-month PFS rate in a total of 58 patients was only numerically higher in the DP+C arm (61%) compared with the DP arm (57%). Similarly, the 6-month OS rate, objective tumor and PSA response rates, and biomarkers were not significantly different between the two arms. Increased baseline levels of interleukin 6 (IL-6), however, were significantly associated with increased risk of progression. Neutropenia was the only grade 4 toxicity (38% in the DP+C arm vs. 18% in the DP arm). CONCLUSION:Combining cediranib with docetaxel + prednisone failed to demonstrate superior efficacy, compared with docetaxel + prednisone, and added toxicity. Our data do not support pursuing the combination further in patients with mCRPC.

SUBMITTER: Heath E 

PROVIDER: S-EPMC6738301 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer.

Heath Elisabeth E   Heilbrun Lance L   Mannuel Heather H   Liu Glenn G   Lara Primo P   Monk J Paul JP   Flaig Thomas T   Zurita Amado A   Mack Philip P   Vaishampayan Ulka U   Stella Philip P   Smith Daryn D   Bolton Susan S   Hussain Arif A   Al-Janadi Anas A   Silbiger Daniel D   Usman Muhammad M   Ivy S Percy SP  

The oncologist 20190531 9


<h4>Lessons learned</h4>The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate-resistant prostate cancer (mCRPC).The negative data underscore that, despite a sound biological rationale and supportive early-phase clinical results, adding antiangiogenic agents to docetaxel for mCRPC is a great challenge.<h4>Background</h4>Inhibition of vascular endothelial growth factor (VE  ...[more]

Similar Datasets

| S-EPMC4425389 | biostudies-literature
| S-EPMC9527760 | biostudies-literature
| S-EPMC4307981 | biostudies-literature
| S-EPMC8265825 | biostudies-literature
| S-EPMC9886492 | biostudies-literature
| S-EPMC7319102 | biostudies-literature
| S-EPMC7467473 | biostudies-literature
| S-EPMC4415089 | biostudies-literature
| S-EPMC5785489 | biostudies-literature
| S-EPMC6413557 | biostudies-literature